Swiss pharmaceutical company Novartis envisions a world where access to healthcare is not a privilege but a fundamental human right, and this vision drives its global health initiatives. Yet, many systemic barriers, including health system, sociocultural, and financial barriers, prevent people from accessing the healthcare they need. Addressing these barriers requires a comprehensive approach across the value chain, including policy changes, investment in healthcare infrastructure, workforce development, health education, and community engagement. It also requires public-private partnerships that support local health needs and foster long-term sustainability – critical success factors to deliver impact at scale.
Against this background, Novartis is collaborating with governments, non-profit organizations, and local partners to help overcome these challenges and achieve global health equity.
One example of the company’s commitment to equitable healthcare is its comprehensive sickle cell disease program in sub-Saharan Africa. This initiative encompasses the entire healthcare value chain, from newborn screening to disease management. Novartis collaborates with various stakeholders to ensure proper diagnosis, treatment, and affordable access to medicines, setting a "blueprint" for future global health programs.
As the global cancer burden continues to rise, low- and middle-income countries are disproportionately affected in terms of cancer cases and deaths. Partnering with The Max Foundation, Novartis helps to improve accessibility to innovative medicines by providing people living with certain cancers in nearly 70 lower-income countries with medicines free of charge. Additionally, as a member of the City Cancer Challenge, Novartis leverages city governments and stakeholders to drive sustainable solutions for cancer care in Ghana and Paraguay. Further, Novartis was the first pharmaceutical company to contribute an innovative medicine to the Access To Oncology Medicines coalition, a public-private partnership aimed at building a new sustainable model for access to cancer medicines.
Active in the fight against malaria, a preventable and treatable disease that causes more than 600,000 deaths every year, Novartis has delivered over 1 billion malaria treatments to endemic countries since 1999. The company's malaria R&D program focuses on next-generation medicines to combat artemisinin resistance. Novartis is also developing a formulation for babies under 5kg suffering from malaria, a patient population currently lacking approved treatment options.
Novartis has also played a pivotal role in leprosy elimination by donating Multidrug Therapy, a groundbreaking treatment that has reduced the global burden of leprosy by 95% over four decades, to the World Health Organization.
As a global pharmaceutical leader, Novartis wants to be part of the solution to global health equity. Collaboration between public and private sectors, combined with a holistic view of the healthcare ecosystem, is crucial in bridging the healthcare access gap and moving toward a more just and equitable world. The company’s unwavering dedication to health equity and innovative solutions underscores its belief that healthcare is a fundamental human right.
